Please assess the completion status of the following clinical trial:

Trial Title: Trial to Assess the Impact of PrEP to Tenofovir Gel on the Efficacy of Tenofovir-containing ART on Viral Suppression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Previously enrolled in the CAPRISA 004 or CAPRISA 008 study - placebo or active arms~* Able and willing to provide informed consent to be screened for, and to enrol in, the study~* Able and willing to provide adequate locator information for study retention purposes~* Confirmed HIV infection in the CAPRISA 004 or 008 trial~* Agree to adhere to study visits and procedures~Exclusion Criteria:~* Currently on antiretroviral therapy (including PMTCT prophylaxis)~* Has any other condition that, based on the opinion of the Investigator or designee, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Tenofovir, lamivudine and efavirenz (Type: EXPERIMENTAL): None
- Zidovudine, lamivudine and efavirenz (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).